427
Views
10
CrossRef citations to date
0
Altmetric
Review

How is patient care for multiple myeloma advancing?

, , , &
Pages 551-561 | Received 31 Oct 2016, Accepted 02 May 2017, Published online: 19 May 2017
 

ABSTRACT

Introduction: Treatment of multiple myeloma has undergone profound changes in the past years thanks to the increased understanding of the biology of the disease and the new treatment options. New drugs and effective approaches are currently available for the treatment of multiple myeloma, including immunomodulatory agents, proteasome inhibitors and autologous stem cell transplantation.

Areas covered: We have described the recent updated criteria to start treatment in multiple myeloma and summarized clinical data from major studies including most recent agents. Particularly, results with pomalidomide, carfilzomib, ixazomib, monoclonal antibodies such as elotuzumab, daratumumab, and checkpoint inhibitors have been reported. Both transplant and non-transplant settings have been covered.

Expert commentary: Despite the successful improvement in overall survival and time to relapse, multiple myeloma still remains incurable. Therefore, there is still an unmet need for new treatment strategies with novel mechanisms of action, like monoclonal antibodies, novel immunomodulators, and novel proteasome inhibitors. Implementation of these novel drugs in rationally designed therapies with a good balance of efficacy and safety should be carefully considered in order to improve outcome.

Acknowledgments

The authors thank Giorgio Schirripa for assistance in preparing the manuscript.

Declaration of interest

A Larocca has received honoraria from Amgen, BMS, Celgene and Janssen-Cilag. S Bringhen has received honoraria from BMS, Celgene, Janssen-Cilag, and is on the advisory board for Amgen, Mundipharma and Karyopharm. M Boccadoro has reviewed honoraria from Sanofi, Celgene, Amgen, Janssen, Novartis, Abbivie, BMS, and research funding from Celgene, Janssen, Amgen, BMS, Mundipharma, Novartis and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This manuscript was not funded.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 435.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.